Volume 17, Number 2—February 2011
Pandemic (H1N1) 2009, Abu Dhabi, United Arab Emirates, May 2009–March 2010
|Gender, no. (%)|
|Nationality, no. (%)|
|United Arab Emirates||12 (46.2)|
|Signs and symptoms, no. (%)|
|Breathing difficulty||14 (53.8)|
| Other,* with or without above symptoms
|Underlying conditions, no. (%)|
|Cardio/cerebrovascular disease||2 (7.7)|
| Not recorded
|Duration of oseltamivir treatment, d†|
|Time from laboratory confirmation of pandemic (H1N1) 2009 infection to start of oseltamivir treatment, d‡|
||−16 to 2
|Duration from hospitalization to death, d|
*Sore throat, lung infiltration, diarrhea, headache, chest pain, abdominal pain.
†Although all patients with pandemic (H1N1) 2009 were treated with oseltamivir, the exact duration of treatment was known for only 12.
‡The exact date of laboratory confirmation of pandemic (H1N1) 2009 and start of oseltamivir treatment was known for only 21 of the 26 patients.
- Page created: July 13, 2011
- Page last updated: July 13, 2011
- Page last reviewed: July 13, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)